Search Results - "ROTTEY, Sylvie"

Immune checkpoint inhibitors in treatment of soft-tissue sarcoma: A systematic review and meta-analysis by Saerens, Michael, Brusselaers, Nele, Rottey, Sylvie, Decruyenaere, Alexander, Creytens, David, Lapeire, Lore

“…Soft-tissue sarcomas (STSs) are rare malignancies, accounting for approximately 1% of adult cancer. Metastatic disease carries a poor prognosis, and various…”
Get full text

Trastuzumab duocarmazine in locally advanced and metastatic solid tumours and HER2-expressing breast cancer: a phase 1 dose-escalation and dose-expansion study by Banerji, Udai, Prof, van Herpen, Carla M L, Prof, Saura, Cristina, MD, Thistlethwaite, Fiona, MD, Lord, Simon, MD, Moreno, Victor, MD, Macpherson, Iain R, MD, Boni, Valentina, MD, Rolfo, Christian, Prof, de Vries, Elisabeth G E, Prof, Rottey, Sylvie, Prof, Geenen, Jill, MD, Eskens, Ferry, MD, Gil-Martin, Marta, MD, Mommers, Ellen C, PhD, Koper, Norbert P, PhD, Aftimos, Philippe, MD

“…SummaryBackgroundTrastuzumab duocarmazine is a novel HER2-targeting antibody–drug conjugate comprised of trastuzumab covalently bound to a linker drug…”
Get full text

Safety and pharmacokinetics of islatravir subdermal implant for HIV-1 pre-exposure prophylaxis: a randomized, placebo-controlled phase 1 trial by Matthews, Randolph P., Patel, Munjal, Barrett, Stephanie E., Haspeslagh, Liesbeth, Reynders, Tom, Zhang, Saijuan, Rottey, Sylvie, Goodey, Adrian, Vargo, Ryan C., Grobler, Jay A., Stoch, S. Aubrey, Iwamoto, Marian

“…Islatravir (MK-8591) is a highly potent type 1 human immunodeficiency virus (HIV-1) nucleoside reverse transcriptase translocation inhibitor with a long…”
Get full text

Very late xerostomia, dysphagia, and neck fibrosis after head and neck radiotherapy by Baudelet, Margot, Van den Steen, Leen, Tomassen, Peter, Bonte, Katrien, Deron, Philippe, Huvenne, Wouter, Rottey, Sylvie, De Neve, Wilfried, Sundahl, Nora, Van Nuffelen, Gwen, Duprez, Fréderic

“…Background Acute and late toxicity after intensity‐modulated radiotherapy (IMRT) for head and neck cancer (HNC) impacts on patient quality of life; yet, very…”
Get full text

Cisplatin and fluorouracil with or without panitumumab in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck (SPECTRUM): an open-label phase 3 randomised trial by Vermorken, Jan B, Dr, Stöhlmacher-Williams, Jan, MD, Davidenko, Irina, MD, Licitra, Lisa, MD, Winquist, Eric, MD, Villanueva, Cristian, MD, Foa, Paolo, MD, Rottey, Sylvie, MD, Skladowski, Krzysztof, MD, Tahara, Makoto, MD, Pai, Vasant R, MD, Faivre, Sandrine, MD, Blajman, Cesar R, MD, Forastiere, Arlene A, MD, Stein, Brian N, MBBS, Oliner, Kelly S, PhD, Pan, Zhiying, PhD, Bach, Bruce A, MD

“…Summary Background Previous trials have shown that anti-EGFR monoclonal antibodies can improve clinical outcomes of patients with recurrent or metastatic…”
Get full text

Platinum-Based Chemotherapy plus Cetuximab in Head and Neck Cancer by Vermorken, Jan B, Mesia, Ricard, Rivera, Fernando, Remenar, Eva, Kawecki, Andrzej, Rottey, Sylvie, Erfan, Jozsef, Zabolotnyy, Dmytro, Kienzer, Heinz-Roland, Cupissol, Didier, Peyrade, Frederic, Benasso, Marco, Vynnychenko, Ihor, De Raucourt, Dominique, Bokemeyer, Carsten, Schueler, Armin, Amellal, Nadia, Hitt, Ricardo

“…This randomized trial of the treatment of advanced head and neck cancer tested the efficacy of adding cetuximab, an antibody against the epidermal growth…”
Get full text

The Therapeutic Landscape of Salivary Gland Malignancies-Where Are We Now? by Cleymaet, Robbert, Vermassen, Tijl, Coopman, Renaat, Vermeersch, Hubert, De Keukeleire, Stijn, Rottey, Sylvie

“…Salivary gland malignancies (SGMs) account for less than 5% of new diagnoses in head and neck tumors. If feasible, surgery is the preferred treatment modality…”
Get full text

Phase I Dose-Escalation Study of the Anti-CD70 Antibody ARGX-110 in Advanced Malignancies by Aftimos, Philippe, Rolfo, Christian, Rottey, Sylvie, Offner, Fritz, Bron, Dominique, Maerevoet, Marie, Soria, Jean-Charles, Moshir, Mahan, Dreier, Torsten, Van Rompaey, Luc, Michot, Jean-Marie, Silence, Karen, Hultberg, Anna, Gandini, Domenica, de Haard, Hans, Ribrag, Vincent, Peeters, Marc, Thibault, Alain, Leupin, Nicolas, Awada, Ahmad

“…The purpose of this study was to evaluate safety, pharmacokinetics, pharmacodynamics, and preliminary antitumor efficacy of ARGX-110, a glyco-engineered…”
Get full text

A phase II study of monalizumab in patients with recurrent/metastatic squamous cell carcinoma of the head and neck: The I1 cohort of the EORTC-HNCG-1559 UPSTREAM trial by Galot, Rachel, Le Tourneau, Christophe, Saada-Bouzid, Esma, Daste, Amaury, Even, Caroline, Debruyne, Philip, Henry, Stéphanie, Zanetta, Sylvie, Rutten, Anemie, Licitra, Lisa, Canon, Jean-Luc, Kaminsky, Marie-Christine, Specenier, Pol, Rottey, Sylvie, Guigay, Joël, Kong, Anthony, Tinhofer, Inge, Borcoman, Edith, Dirix, Lieve, Raveloarivahy, Tiana, Fortpied, Catherine, Vanlancker, Maureen, Morfouace, Marie, Govaerts, Anne-Sophie, Machiels, Jean-Pascal

“…Monalizumab is a monoclonal antibody targeting the inhibitory natural killer group 2A (NKG2A) receptor localised on natural killer (NK) and T cells. Its…”
Get full text

A Randomized, Double-Blind, Placebo-Controlled, Phase 1 Trial of Radiopaque Islatravir-Eluting Subdermal Implants for Pre-exposure Prophylaxis Against HIV-1 Infection by Matthews, Randolph P., Zang, Xiaowei, Barrett, Stephanie E., Koynov, Athanas, Goodey, Adrian, Heimbach, Tycho, Weissler, Vanessa L., Leyssens, Carlien, Reynders, Tom, Xu, Zhiqing, Rottey, Sylvie, Vargo, Ryan, Robertson, Michael N., Stoch, S. Aubrey, Iwamoto, Marian

“…Islatravir (MK-8591) is a deoxyadenosine analog in development for the treatment and prevention of HIV-1 infection. An islatravir-eluting implant could provide…”
Get full text

A phase 1a/1b trial of CSF-1R inhibitor LY3022855 in combination with durvalumab or tremelimumab in patients with advanced solid tumors by Falchook, Gerald S., Peeters, Marc, Rottey, Sylvie, Dirix, Luc Y., Obermannova, Radka, Cohen, Jonathan E., Perets, Ruth, Frommer, Ronnie Shapira, Bauer, Todd M., Wang, Judy S., Carvajal, Richard D., Sabari, Joshua, Chapman, Sonya, Zhang, Wei, Calderon, Boris, Peterson, Daniel A.

“…Summary Background LY3022855 is a recombinant, immunoglobulin, human monoclonal antibody targeting the colony-stimulating factor-1 receptor. This phase 1 trial…”
Get full text

TILs in Head and Neck Cancer: Ready for Clinical Implementation and Why (Not)? by De Meulenaere, Astrid, Vermassen, Tijl, Aspeslagh, Sandrine, Vandecasteele, Katrien, Rottey, Sylvie, Ferdinande, Liesbeth

“…The assessment of tumor infiltrating lymphocytes (TILs) has recently emerged as a prognostic biomarker in several solid tumors. Quantification and subtyping of…”
Get full text

Turning the tide: Clinical utility of PD-L1 expression in squamous cell carcinoma of the head and neck by De Meulenaere, Astrid, Vermassen, Tijl, Aspeslagh, Sandrine, Huvenne, Wouter, Van Dorpe, Jo, Ferdinande, Liesbeth, Rottey, Sylvie

“…Highlights • No consensus on PD-L1 expression on tumour cells exists in literature. • A more standardised methodology for assessment PD-L1 expression is…”
Get full text

Efficacy and Safety of Pazopanib in Patients With Metastatic Renal Cell Carcinoma by HUTSON, Thomas E, DAVIS, Ian D, PANDITE, Lini, FIGLIN, Robert A, MACHIELS, Jean-Pascal H, DE SOUZA, Paul L, ROTTEY, Sylvie, HONG, Bao-Fa, EPSTEIN, Richard J, BAKER, Katherine L, MCCANN, Lauren, CROFTS, Theresa

“…Inactivation of the von Hippel-Lindau gene in clear-cell renal cell carcinomas (RCC) leads to overexpression of hypoxia inducible factor, a transcription…”
Get full text

Infrared Spectroscopy: A New Frontier in Hematological Disease Diagnosis by Delrue, Charlotte, Speeckaert, Reinhart, Oyaert, Matthijs, Kerre, Tessa, Rottey, Sylvie, Coopman, Renaat, Huvenne, Wouter, De Bruyne, Sander, Speeckaert, Marijn M

“…Hematological diseases, due to their complex nature and diverse manifestations, pose significant diagnostic challenges in healthcare. The pressing need for…”
Get full text

A phase 1 dose escalation study of the oncolytic adenovirus enadenotucirev, administered intravenously to patients with epithelial solid tumors (EVOLVE) by Machiels, Jean-Pascal, Salazar, Ramon, Rottey, Sylvie, Duran, Ignacio, Dirix, Luc, Geboes, Karen, Wilkinson-Blanc, Christine, Pover, Gillian, Alvis, Simon, Champion, Brian, Fisher, Kerry, McElwaine-Johnn, Hilary, Beadle, John, Calvo, Emiliano

“…Enadenotucirev is a chimeric adenovirus with demonstrated preclinical tumor-selective cytotoxicity and a short half-life. Further clinical mechanism of action…”
Get full text

Glycosylation of prostate specific antigen and its potential diagnostic applications by Vermassen, Tijl, Speeckaert, Marijn M., Lumen, Nicolaas, Rottey, Sylvie, Delanghe, Joris R.

“…Prostate specific antigen (PSA) assays are widely used for early detection of prostate cancer. However, those analyses are associated with considerable…”
Get full text

Outcomes of adjuvant immune checkpoint inhibitor therapy in melanoma: a retrospective study by Sarah, Fieuws, Margot, De Ridder, Valerie, Baert, Alexander, Decruyenaere, Lieve, Brochez, Sylvie, Rottey, Celine, Jacobs, Michael, Saerens

“…Adjuvant treatment of malignant melanoma has improved the outcomes for patients. However, real-world data on efficacy and safety are limited. We investigated…”
Get full text

A Phase 1 Study of mTORC1/2 Inhibitor BI 860585 as a Single Agent or with Exemestane or Paclitaxel in Patients with Advanced Solid Tumors by de Braud, Filippo, Machiels, Jean-Pascal H., Boggiani, Daniela, Rottey, Sylvie W.H., Duca, Matteo, Laruelle, Marie, Salvagni, Stefania, Damian, Silvia, Lapeire, Lore D.F., Tiseo, Marcello, Dermine, Alexandre, Ould-Kaci, Mahmoud, Braunger, Juergen, Rascher, Juliane, Fischer, Daniela, Hoefler, Josef, Mariani, Gabriella L., Cresta, Sara

“…This phase 1 trial (NCT01938846) determined the maximum tolerated dose (MTD) of the mTOR serine/threonine kinase inhibitor, BI 860585, as monotherapy and with…”
Get full text

Evaluating the impact of 18F-FDG-PET-CT on risk stratification and treatment adaptation for patients with muscle-invasive bladder cancer (EFFORT-MIBC): a phase II prospective trial by Verghote, Flor, Poppe, Lindsay, Verbeke, Sofie, Dirix, Piet, Albersen, Maarten, De Meerleer, Gert, Berghen, Charlien, Ost, Piet, Villeirs, Geert, De Visschere, Pieter, De Man, Kathia, De Maeseneer, Daan, Rottey, Sylvie, Van Praet, Charles, Decaestecker, Karel, Fonteyne, Valérie

“…The outcome of patients with muscle-invasive bladder cancer (MIBC) remains poor, despite aggressive treatments. Inadequate primary staging, classically…”
Get full text